HylaPharm is a drug delivery company now producing its patented HylaPlat technology, which delivers chemotherapy drugs directly to cancer cells in tumors and nearby lymph nodes while limiting drug exposure in kidneys, nerves and auditory organs. By limiting exposure in these surrounding areas, HylaPlat enables targeted treatments with fewer side effects.
Immunogenetix Therapeutics, Inc. is an early stage biotechnology company developing advanced DNA-based therapies for the prevention and treatment of HIV infection. DNA-based therapies offer significant advantages over recombinant protein therapies, including an enhanced cellular immune response and long-term protection against viral diseases that require cellular immunity (e.g. HIV). The Company has exclusive worldwide rights to proprietary therapeutic candidates and supporting technologies.
Innara Health TM formerly KC BioMediX, Inc. is a medical device company that was established to commercialize technologies developed at the University of Kansas for the care and treatment of infants born prematurely. Specifically, the company is developing medical devices based upon technologies that measure, monitor and develop the non-nutritive suck – an essential building block in an infant’s development of the coordinated sucking, breathing and swallowing capability needed for independent oral feed.
KanPro Research, LLC is a contract research organization (CRO) headquartered in the Bioscience & Technology Business Center at the University of Kansas. The company specializes in recombinant protein expression and purification from mammalian and cell-free systems. KanPro seeks contract research partnerships with academic and industrial researchers. The company has special expertise in producing challenging proteins including those that have previously failed. KanPro Research also manufactures, tests biochemical reagents, kits and equipment and provides advice and consultation services.